Fig 1: Effects of NSO on serum levels of TNF-α, IL-1β, IL-10, BDNF, and NPY in LPS-challenged rats. (A) TNF-α; (B) IL-1β; (C) IL-10; (D) BDNF; (E) NPY. C—control group; LPS-C—LPS-control group; NSO-3—group treated with NSO 3 mL/kg BW; NSO-5—group treated with NSO 5 mL/kg BW. Data are expressed as mean ± SEM (n = 8). * p < 0.05 compared to C; ** p < 0.01 compared to C; *** p < 0.001 compared to C; + p < 0.05 compared to LPS-C; ++ p < 0.01 compared to LPS-C.
Fig 2: Impact of NSO on circulating IL-10, IL-1β, TNF-α, NPY, and BDNF levels in CFA-induced arthritis. (A). IL-10, (B). IL-1β, (C). TNF-α, (D). NPY, and (E). BDNF. Data are expressed as mean ± SD. a p < 0.05 vs. C; b p < 0.01 vs. C; c p < 0.001 vs. C; d p < 0.05 vs. CFA-C; e p < 0.01 vs. CFA-C; ns—not significant vs. C.
Supplier Page from CUSABIO Technology LLC for Rat neuropeptide Y (NPY) ELISA Kit